Weeks 1 through 12 showed moderate but accelerating weight loss as titration progressed
Tonneijck L, Muskiet MH, Smits MM, et al
Stay Physically Active Exercise becomes even more important after stopping
The first, degradation resistant analogs of GLP-1 (Exenatide and Liraglutide) must be given by subcutaneous injection once or twice daily
It is also important to be vigilant about symptoms that may indicate kidney stress during treatment, including: Reduced urine output or dark-coloured urine Swelling in the legs or ankles Persistent nausea, fatigue, or confusion Flank or lower back pain If any of these symptoms develop after starting a weight loss medication, you should stop the medication and seek medical advice promptly
BPC-157 ClinicalTrials.gov Registry: NCT07437547 Status & Full Trial History ClinicalTrials.gov lists just 2 BPC-157 trials: the recruiting NCT07437547 Phase 2 hamstring study and a 2015 Phase 1 pilot with no results ever posted
